COMPANY:

NeoGenomics

"NeoGenomics...will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 demonstrating high concordance between its RaDaR® ST and RaDaR® 1.0 assays for detecting molecular residual disease (MRD) in solid tumors. NeoGenomics will also present on the progress of its NextGen (whole genome-based) MRD research program, as well as three additional posters highlighting the company’s work in liquid biopsy and genomic profiling across solid tumor types."

"NeoGenomics...today announced the presentation of assay-relevant data, including interventional therapy trials in progress, to showcase how its molecular residual disease (MRD) assay may benefit pharmaceutical partners at the European Society for Medical Oncology (ESMO) Congress 2025, October 17–21, in Berlin, Germany. RaDaR ST, the company’s circulating tumor DNA (ctDNA) assay, is designed to accelerate and optimize oncology drug development."

"Natera, Inc...today provided an update regarding its intellectual property litigation with NeoGenomics, Inc...The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents that Natera asserted against NeoGenomics’ v1.1 RaDaR test. Natera is evaluating its options, including an appeal and further enforcement with other patents."

"NeoGenomics...today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company’s PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable."

"Owkin...today announced a strategic agreement with NeoGenomics...and France Tissue Bank (FTB). Owkin will leverage their respective high-quality histopathological datasets to develop the first foundation model exclusively trained on immunohistochemistry (IHC) images and made available publicly for research use."

"NeoGenomics, Inc...today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confidently."

"NeoGenomics, Inc...announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay. The test is now available to oncologists and pathologists nationwide, supporting treatment selection for patients with advanced non-small cell lung cancer (NSCLC) with a 48-hour turnaround time....It is designed to help identify patients who may be eligible for newly approved targeted therapies, including EMRELIS (telisotuzumab vedotin-tllv), which was recently approved by the U.S. Food and Drug Administration (FDA)."

"NeoGenomics...today announced it has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey."

"NeoGenomics...announced the recent publication of a new study in ESMO Open, demonstrating how circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) may enable earlier identification of disease recurrence for high-risk melanoma patients...Utilizing RaDaR®, NeoGenomics’ next-generation sequencing assay, researchers found that ctDNA detection after surgery can identify patients with worse prognosis, and serial ctDNA measurements may enable earlier identification of disease recurrence."

"NeoGenomics, Inc...will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10. The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel."

"NeoGenomics...will present four abstracts at the Association for Molecular Pathology (AMP) 2024...The study highlights the G4 platform as a reliable and efficient alternative for clinical and genomic research applications, delivering high accuracy, speed, and flexibility...The data shows that the TSO500 ctDNA v2 assay maintains high sensitivity for detecting tumor mutations, even with significant genomic DNA contamination, ensuring reliable results for cancer profiling through liquid biopsy...The study validates an improved workflow for the Neo Comprehensive solid tumor genome profiling NGS panel, offering significant time savings and reducing errors while maintaining equivalent accuracy and performance....The data demonstrates that NeoGenomics’ bioinformatics pipeline can identify and classify HPV cases into high and low-risk subtypes with similar performance to more traditional methods, delivering added value and potential cost savings for patients."

"Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City."